The MK-4482-002 study will test the safety and effectiveness of an investigational antiviral study drug which may reduce symptoms and recovery time for people who tested positive for COVID-19 in the last 5 days. This clinical study will help researchers learn whether the study drug:
There are rules in place to help protect the rights, safety, and well-being of people who volunteer for research studies. These rules are put in place to make sure studies follow strict scientific and ethical guidelines. Before a clinical research study can begin, a review board must review the study. This group is called an IRB or institutional review board. An IRB is made up of doctors, scientists, and members of the community.
To participate in the MK-4482-002 study, participants must be 18 years or older and:
The study doctor and staff can provide you with information about additional requirements for participation.
Below is a list of common COVID-19 signs and symptoms someone may be experiencing if they have COVID-19.
This study will have participants involved for about 7 months over 3 trial phases.
A clinical trial is a research study that tries to answer questions about how medicines work in the people who take them. Researchers run studies to test whether an investigational medication is safe and effective. These studies may help doctors find new ways to help prevent, detect, or treat health problems. Information learned from this clinical research study may help other people in the future. Additional care may also be provided for COVID-19 for those participating. This may include:
Taking part in this study is voluntary and the participant may stop at any time for any reason. In addition, there is no cost for the study drug or study-related care, tests and exams.
If you would like to see if you are eligible to participate, please find a site near you.Find a site near you
If you're interested in learning more about the MK-4482-002 study, including potential risks and benefits of participation, you can find additional details here.